NRP1 and neoplasm: Therefore, we set out to develop NRP-1-targeting nanobodies (Nbs), as these antigen-binding moieties, derived from camelid heavy chain only antibodies, are small in size (12–15 kDa), have a strong tumor-penetrating potential and their single-domain nature allows molecular engineering [17,18,19].